联合增强与扩散加权MRI制定RECIST识别贝伐珠单抗治疗的结直肠癌肝转移瘤反应
本研究纳入126例贝伐珠单抗化疗后行肝切除的结直肠癌肝转移患者,在初始分析队列(42例,76个目标肝转移灶)中确定动脉强化面积下降百分比和ADC值升高百分比鉴别病理主要与次要反应的最佳截断值(约33%和19%),并据此建立联合功能与大小条目的D-RECIST,在验证队列中D-RECIST定义的反应者无病生存期显著长于非反应者,而RECIST无显著差异。
要点
- 动脉强化面积下降约33%和ADC值升高约19%可鉴别结直肠癌肝转移的病理主要与次要反应。
- D-RECIST定义的反应者中位无病生存期12.9个月,显著长于非反应者的8.6个月(p=0.021)。
- RECIST定义的反应者与非反应者无病生存期无显著差异(p=0.524)。
核心结论
- D-RECIST定义的反应提供显著预后信息,可能作为贝伐珠单抗治疗的结直肠癌肝转移优于RECIST的反应评价方法。
研究设计与样本
- 本研究为开发与验证研究,共纳入126例接受含贝伐珠单抗化疗后行肝切除的结直肠癌肝转移患者。
- 初始分析队列42例(76个目标肝转移灶),验证队列84例。
- 测量从基线至化疗后动脉强化面积下降百分比和表观扩散系数(ADC)值升高百分比,以病理证实的病理主要与次要反应为参考确定最佳截断值。
- 将功能学条目与大小条目联合建立D-RECIST,并在验证队列中检验D-RECIST与RECIST的生存相关性。
关键影像表现/征象
- 动脉强化面积下降百分比在病理主要与次要反应病灶间有显著差异,最佳截断值约为33%。
- ADC值升高百分比在病理主要与次要反应病灶间有显著差异,最佳截断值约为19%。
诊断标准与关键数值
- 动脉强化面积下降百分比最佳截断值约为33%,用于鉴别病理主要与次要反应。
- ADC值升高百分比最佳截断值约为19%,用于鉴别病理主要与次要反应。
- D-RECIST由功能学条目与大小条目联合建立,其定义的反应者中位无病生存期12.9个月,非反应者8.6个月(p=0.021)。
- RECIST定义的反应者与非反应者中位无病生存期无显著差异(p=0.524)。
- Cox回归模型中,D-RECIST定义的反应独立预测无病生存期(p=0.034),RECIST定义的反应未独立预测(p=0.811)。
临床应用与阅片要点
- 在贝伐珠单抗治疗的结直肠癌肝转移中,可结合动脉强化面积下降百分比与ADC值升高百分比等功能学改变辅助评价反应。
- 作者认为D-RECIST定义的反应提供显著预后信息,可能作为优于RECIST的反应评价方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Response evaluation criteria in solid tumors (RECIST) often fail to identify clinically meaningful response to bevacizumab-containing therapy in colorectal liver metastasis (CRLM). This study aimed to develop RECIST by combining contrast-enhanced and diffusion-weighted magnetic resonance imaging (MRI).
METHODS: A total of 126 patients with CRLM who underwent hepatic resection after bevacizumab-containing chemotherapy were split into initial analyses cohort (N = 42, with 76 indexed liver metastases) and validation cohort (N = 84). In lesion-based analyses, percentage decrease of arterial enhancement area and percentage increase of apparent diffusion coefficient (ADC) value from baseline to post-chemotherapy were measured. Their optimal cutoff values for distinguishing pathology-confirmed major and minor response were determined. Then, the developed RECIST (D-RECIST) was established by combining functional and size-based items. Survival relevance of D-RECIST and RECIST was examined in the validation cohort.
RESULTS: Percentage decrease of arterial enhancement area and increase of ADC value significantly differed between lesions of pathologic major or minor response, with optimal cutoffs of approximately 33% and 19%, respectively. Patients defined as responders by D-RECIST had a significantly longer median disease-free survival (DFS) than non-responders (p = 0.021; 12.9 versus 8.6 months). No significant difference was observed with RECIST (p = 0.524). In a Cox regression model, D-RECIST- but not RECIST-defined responses independently predicted the DFS (p = 0.034 and 0.811).
CONCLUSIONS: D-RECIST-defined responses provided significant prognostic information, and thus may serve as a better response evaluation approach than RECIST in CRLM treated with bevacizumab-containing therapy.
KEY POINTS: • Changes in arterial enhancement area and apparent diffusion coefficient value are associated with pathological response in colorectal liver metastases treated with bevacizumab. • The MRI-based response criteria developed by combining size-based and functional features can provide significant prognostic information.
引用
- Liu LH, Zhou GF, Lv H, et al. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI. Eur Radiol. 2021. PMID: 33449175. doi:10.1007/s00330-020-07647-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。